BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23651223)

  • 1. A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.
    Sheng R; Sun H; Liu L; Lu J; McEachern D; Wang G; Wen J; Min P; Du Z; Lu H; Kang S; Guo M; Yang D; Wang S
    J Med Chem; 2013 May; 56(10):3969-79. PubMed ID: 23651223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.
    Sun H; Liu L; Lu J; Bai L; Li X; Nikolovska-Coleska Z; McEachern D; Yang CY; Qiu S; Yi H; Sun D; Wang S
    J Med Chem; 2011 May; 54(9):3306-18. PubMed ID: 21462933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
    Peng Y; Sun H; Lu J; Liu L; Cai Q; Shen R; Yang CY; Yi H; Wang S
    J Med Chem; 2012 Jan; 55(1):106-14. PubMed ID: 22148838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.
    Cai Q; Sun H; Peng Y; Lu J; Nikolovska-Coleska Z; McEachern D; Liu L; Qiu S; Yang CY; Miller R; Yi H; Zhang T; Sun D; Kang S; Guo M; Leopold L; Yang D; Wang S
    J Med Chem; 2011 Apr; 54(8):2714-26. PubMed ID: 21443232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
    Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
    Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, in silico evaluation, and in vitro verification of new bivalent Smac mimetics with pro-apoptotic activity.
    Huang Q; Peng Y; Peng Y; Lin H; Deng S; Feng S; Wei Y
    Methods; 2024 Apr; 224():35-46. PubMed ID: 38373678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
    Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
    Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
    Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
    Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer.
    Zhang T; Li Y; Zou P; Yu JY; McEachern D; Wang S; Sun D
    Biopharm Drug Dispos; 2013 Sep; 34(6):348-59. PubMed ID: 23813446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.
    Sun H; Nikolovska-Coleska Z; Lu J; Meagher JL; Yang CY; Qiu S; Tomita Y; Ueda Y; Jiang S; Krajewski K; Roller PP; Stuckey JA; Wang S
    J Am Chem Soc; 2007 Dec; 129(49):15279-94. PubMed ID: 17999504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
    Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
    J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic.
    Sun H; Nikolovska-Coleska Z; Lu J; Qiu S; Yang CY; Gao W; Meagher J; Stuckey J; Wang S
    J Med Chem; 2006 Dec; 49(26):7916-20. PubMed ID: 17181177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP).
    Sun H; Stuckey JA; Nikolovska-Coleska Z; Qin D; Meagher JL; Qiu S; Lu J; Yang CY; Saito NG; Wang S
    J Med Chem; 2008 Nov; 51(22):7169-80. PubMed ID: 18954041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
    Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
    Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.